Literature DB >> 27146151

Ovarian stimulation in the luteal phase: systematic review and meta-analysis.

C E Boots1, M Meister2, A R Cooper2, A Hardi3, E S Jungheim2.   

Abstract

PURPOSE: The purpose of this study was to evaluate whether outcomes are different if controlled ovarian stimulation (COS) is started in the luteal phase rather than the follicular phase.
METHODS: A systematic review and meta-analysis was performed. Sixteen studies were included in the qualitative analysis, and eight studies with a total of 338 women were included in the quantitative analysis.
RESULTS: Cycles initiated in the luteal phase were slightly longer (WMD 1.1 days, 95 % CI 0.39-1.9) and utilized more total gonadotropins (WMD 817 IU, 95 % CI 489-1144). However, no differences were noted in peak estradiol levels (WMD -411 pg/ml, 95 % CI -906-84.7) or in the total number of oocytes retrieved (WMD 0.52 oocytes, 95 % CI -0.74-1.7). There were slightly more mature oocytes retrieved in the luteal phase (WMD 0.77 oocytes, 95 % CI 0.21-1.3), and fertilization rates were significantly higher (WMD 10 %, 95 % CI 0.03-0.18). While only three studies reported pregnancy outcomes, no difference was noted in the FET pregnancy rates after COS in the luteal versus follicular phase (RR 0.95, 95 % CI 0.56-1.7). A post hoc power analysis revealed that a sample of this size was sufficient to detect a clinically meaningful difference of 2 oocytes retrieved with 93 % power.
CONCLUSION: Although initiating COS in the luteal phase requires a longer stimulation and a higher dose of total gonadotropin, these differences are not clinically significant. Furthermore, COS initiated in the luteal phase does not compromise the quantity or quality of oocytes retrieved compared to outcomes of traditional stimulation in the follicular phase.

Entities:  

Keywords:  Controlled ovarian stimulation; Fertility preservation; In vitro fertilization; Luteal phase; Oocyte cryopreservation

Mesh:

Year:  2016        PMID: 27146151      PMCID: PMC4974222          DOI: 10.1007/s10815-016-0721-5

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  34 in total

Review 1.  Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis.

Authors:  Shevach Friedler; Onder Koc; Yariv Gidoni; Arieh Raziel; Raphael Ron-El
Journal:  Fertil Steril       Date:  2011-11-10       Impact factor: 7.329

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 3.  Fertility preservation for cancer patients. Current options.

Authors:  E Shalom-Paz; H E G Holzer
Journal:  Minerva Ginecol       Date:  2011-12

4.  Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined.

Authors:  Cosima Huober-Zeeb; Barbara Lawrenz; Roxana M Popovici; Thomas Strowitzki; Ariane Germeyer; Petra Stute; Michael von Wolff
Journal:  Fertil Steril       Date:  2010-08-24       Impact factor: 7.329

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation.

Authors:  Ettie Maman; Dror Meirow; Masha Brengauz; Hila Raanani; Jehushua Dor; Ariel Hourvitz
Journal:  Fertil Steril       Date:  2010-08-05       Impact factor: 7.329

7.  Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.

Authors:  Murat Sönmezer; Ilgın Türkçüoğlu; Uğur Coşkun; Kutluk Oktay
Journal:  Fertil Steril       Date:  2011-02-03       Impact factor: 7.329

8.  Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles.

Authors:  Yanping Kuang; Qingqing Hong; Qiuju Chen; Qifeng Lyu; Ai Ai; Yonglun Fu; Zeev Shoham
Journal:  Fertil Steril       Date:  2013-10-23       Impact factor: 7.329

Review 9.  Ovarian stimulation in cancer patients.

Authors:  Hakan Cakmak; Mitchell P Rosen
Journal:  Fertil Steril       Date:  2013-05       Impact factor: 7.329

10.  Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval.

Authors:  Ralf Dittrich; Laura Lotz; Andreas Mueller; Inge Hoffmann; David L Wachter; Kerstin U Amann; Matthias W Beckmann; Thomas Hildebrandt
Journal:  Reprod Biol Endocrinol       Date:  2013-03-05       Impact factor: 5.211

View more
  16 in total

1.  Similar miRNomic signatures characterize the follicular fluids collected after follicular and luteal phase stimulations in the same ovarian cycle.

Authors:  Danilo Cimadomo; Ramona Carmelo; Elvira Immacolata Parrotta; Stefania Scalise; Gianluca Santamaria; Erminia Alviggi; Maria Teresa De Angelis; Gianmarco Sarro; Alberto Vaiarelli; Roberta Venturella; Laura Rienzi; Fulvio Zullo; Filippo Maria Ubaldi; Giovanni Cuda
Journal:  J Assist Reprod Genet       Date:  2019-11-07       Impact factor: 3.412

Review 2.  Oncofertility: Meeting the Fertility Goals of Adolescents and Young Adults With Cancer.

Authors:  H Irene Su; Yuton Tony Lee; Ronald Barr
Journal:  Cancer J       Date:  2018 Nov/Dec       Impact factor: 3.360

3.  A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian stimulation for IVF.

Authors:  Alberto Revelli; Gianluca Gennarelli; Marta Sestero; Stefano Canosa; Andrea Carosso; Francesca Salvagno; Giulia Pittatore; Claudia Filippini; Chiara Benedetto
Journal:  J Assist Reprod Genet       Date:  2020-03-18       Impact factor: 3.412

Review 4.  ART outcomes following ovarian stimulation in the luteal phase:a systematic review and meta-analysis.

Authors:  Buo-Jia Lu; Chien-Ju Lin; Bou-Zenn Lin; Li Huang; Li-Ting Chien; Chi-Huang Chen
Journal:  J Assist Reprod Genet       Date:  2021-05-25       Impact factor: 3.357

5.  Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques.

Authors:  Michael von Wolff; A Germeyer; J Liebenthron; M Korell; F Nawroth
Journal:  Arch Gynecol Obstet       Date:  2017-11-27       Impact factor: 2.344

6.  An extremely patient-friendly and efficient stimulation protocol for assisted reproductive technology in normal and high responders.

Authors:  Chen-Yu Huang; Guan-Yeu Chen; Miawh-Lirng Shieh; Hsin-Yang Li
Journal:  Reprod Biol Endocrinol       Date:  2018-03-05       Impact factor: 5.211

7.  Luteal phase anovulatory follicles result in the production of competent oocytes: intra-patient paired case-control study comparing follicular versus luteal phase stimulations in the same ovarian cycle.

Authors:  Danilo Cimadomo; Alberto Vaiarelli; Silvia Colamaria; Elisabetta Trabucco; Carlo Alviggi; Roberta Venturella; Erminia Alviggi; Ramona Carmelo; Laura Rienzi; Filippo Maria Ubaldi
Journal:  Hum Reprod       Date:  2018-08-01       Impact factor: 6.918

8.  Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients.

Authors:  Ana Paula Cb Campos; Guilherme P Geber; Rodrigo Hurtado; Marcos Sampaio; Selmo Geber
Journal:  JBRA Assist Reprod       Date:  2018-11-01

Review 9.  Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients.

Authors:  Luca Arecco; Marta Perachino; Alessandra Damassi; Maria Maddalena Latocca; Davide Soldato; Giacomo Vallome; Francesca Parisi; Maria Grazia Razeti; Cinzia Solinas; Marco Tagliamento; Stefano Spinaci; Claudia Massarotti; Matteo Lambertini
Journal:  Breast Cancer (Auckl)       Date:  2020-09-04

Review 10.  Recent advances in oncofertility care worldwide and in Japan.

Authors:  Yasushi Takai
Journal:  Reprod Med Biol       Date:  2018-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.